XNAS
MENS
Market cap159mUSD
Oct 08, Last price
2.10USD
1D
1.94%
1Q
-4.98%
IPO
-73.75%
Name
Jyong Biotech Ltd
Chart & performance
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
0.40%
Rev. gr., 5y
%
Revenues
0
Net income
-5m
L+54.72%
CFO
-3m
L-16.09%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Jyong Biotech Ltd. is a Taiwanese biotechnology enterprise dedicated to the research, development, and market introduction of botanical therapeutics, specifically aimed at addressing diseases of the urinary system. Its operations are orchestrated through various subsidiary entities, including Health Ever Bio-Tech and Genvace. The company is actively advancing a robust pipeline of drug candidates, which notably features MCS-2, currently undergoing Phase III trials for benign prostatic hyperplasia (BPH); PCP, which is in Phase II development for prostate cancer; and IC, presently in pre-clinical stages.
Key people
Fu-Feng Kuo
Chairwoman of the Board and Chief Executive Officer · since 2024
Wanwen Su
Chief Scientific Officer · since 2025
Pang-Chief Chi
Independent Director · since 2025
Independent Director · since 2025
Ming Tsan Hsu
Independent Director · since 2025
Valuation
Title in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | ||||||
Unusual Expense (Income) | ||||||
NOPBT | ||||||
NOPBT Margin | ||||||
Operating Taxes | ||||||
Tax Rate | ||||||
NOPAT | ||||||
Net income | ||||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | ||||||
BB yield | ||||||
| Debt | ||||||
Debt current | ||||||
Long-term debt | ||||||
Deferred revenue | ||||||
Other long-term liabilities | ||||||
Net debt | ||||||
| Cash flow | ||||||
Cash from operating activities | ||||||
CAPEX | ||||||
Cash from investing activities | ||||||
Cash from financing activities | ||||||
FCF | ||||||
| Balance | ||||||
Cash | ||||||
Long term investments | ||||||
Excess cash | ||||||
Stockholders' equity | ||||||
Invested Capital | ||||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | ||||||
Price | ||||||
Market cap | ||||||
EV | ||||||
EBITDA | ||||||
EV/EBITDA | ||||||
Interest | ||||||
Interest/NOPBT |